Preterm labour is indicated by regular contractions of the uterus and changes in the cervix (the opening of the womb) before 37 weeks of pregnancy. Preterm labour and birth may be associated with illness or death of the baby, and often place a substantial emotional burden on families. Preterm birth may also result in childhood disability. Even a short-term prolongation of pregnancy after the onset of threatened or actual preterm labour can allow the administration of corticosteroids to the mother to hasten fetal lung maturation and transfer of the mother to a centre with neonatal intensive care facilities. A range of drugs (tocolytic) are used to suppress labour. The oxytocin antagonist atosiban is one of these. Once the episode of threatened preterm labour settles, maintenance treatment with a tocolytic can then be used to try to prevent any reoccurrence. This has to be balanced against potential adverse outcomes such as intrauterine infection, fetal death, an increase in severe disability for survivors, and side-effects of the drugs.
This review identified only one good quality multicentre controlled trial which showed that subcutaneously administered atosiban as maintenance therapy did not reduce the incidence of preterm birth or improve neonatal outcomes when compared with placebo treatment. The trial randomised 513 women in whom preterm labour (with intact membranes and limited cervical dilatation) ceased following intravenous treatment with atosiban. The mean gestation at enrolment was around 31 weeks and the proportion of multiple births was similar in the two groups. Atosiban infused at 6 mL/hr (30 µg/min) did not reduce preterm birth before 28, 32, or 37 weeks. Women on maintenance therapy were discharged home with a continuous subcutaneous infusion pump and daily nursing contact. There was an increase in injection site reaction for the atosiban group. There is insufficient evidence of benefit to justify this intervention.